{"DataElement":{"publicId":"2749891","version":"1","preferredName":"Polymyositis Dermatomyositis Disease or Disorder Involvement Type","preferredDefinition":"Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity; CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response._A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._To have a connection by participation or association or use; sharing in an activity or process._Something distinguishable as an identifiable class based on common qualities.[Manually curated]","longName":"POL_DER_DIS_INV_TYP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2749847","version":"1","preferredName":"Polymyositis Dermatomyositis Disease or Disorder Involvement","preferredDefinition":"Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity; CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response._A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._To have a connection by participation or association or use; sharing in an activity or process.[Manually curated]","longName":"POL_DER_DIS_INV","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2674904","version":"1","preferredName":"Polymyositis Dermatomyositis Diseases and Disorders","preferredDefinition":"Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY, NERVOUS SYSTEM); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9):A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6):A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C26925:C26744:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyositis","conceptCode":"C26925","definition":"An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dermatomyositis","conceptCode":"C26744","definition":"Inflammation of the skin and muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38AF5A24-698D-5552-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-27","modifiedBy":"ONEDATA","dateModified":"2007-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2192548","version":"1","preferredName":"Involvement","preferredDefinition":"To have a connection by participation or association or use; sharing in an activity or process.","longName":"C25548","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9F4C3B9-9218-0989-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-11-29","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D47B8EF-58EF-2534-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2749849","version":"1","preferredName":"Polymyositis Dermatomyositis Involvement Type","preferredDefinition":"Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity; CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response._A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms._To have a connection by participation or association or use; sharing in an activity or process._Something distinguishable as an identifiable class based on common qualities.[Manually curated]","longName":"POL_DER_INV_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"39","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Proximal weakness","valueDescription":"Proximal Muscle Weakness","ValueMeaning":{"publicId":"2749850","version":"1","preferredName":"Proximal Muscle Weakness","longName":"2749850","preferredDefinition":"Proximal; situated nearest to a point of attachment or origin.: A reduction in the strength of one or more muscles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proximal","conceptCode":"C25236","definition":"Situated nearest to a point of attachment or origin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Muscle Weakness","conceptCode":"C50658","definition":"A reduction in the strength of one or more muscles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D47F93B-9991-2D84-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D47F93B-99AA-2D84-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Generalized weakness (including bulbar)","valueDescription":"Generalized Muscle Weakness","ValueMeaning":{"publicId":"2749851","version":"1","preferredName":"Generalized Muscle Weakness","longName":"2749851","preferredDefinition":"Widespread; broadly dispersed.: A reduction in the strength of one or more muscles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Generalized","conceptCode":"C63764","definition":"Widespread, broadly dispersed, common.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Muscle Weakness","conceptCode":"C50658","definition":"A reduction in the strength of one or more muscles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D47F93B-99B9-2D84-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D47F93B-99D2-2D84-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Pulmonary fibrosis","valueDescription":"Pulmonary Fibrosis","ValueMeaning":{"publicId":"2570621","version":"1","preferredName":"Pulmonary Fibrosis","longName":"2570621","preferredDefinition":"Chronic inflammation and progressive fibrosis of the pulmonary alveolar walls, with steadily progressive dyspnea, resulting finally in death from oxygen lack or right heart failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pulmonary Fibrosis","conceptCode":"C26869","definition":"Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E0EA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CZECHS","dateModified":"2008-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D47F93B-99EB-2D84-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Vasculitis","valueDescription":"Vasculitis","ValueMeaning":{"publicId":"2569497","version":"1","preferredName":"Vasculitis","longName":"2569497","preferredDefinition":"Inflammation of a blood vessel.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vasculitis","conceptCode":"C26912","definition":"An inflammatory process involving the wall of the vessels (large, medium, or small-sized vessels). The inflammatory process may cause necrosis or formation of granulomas in the vascular wall. It may be the result of an autoimmune disorder, infection, or malignancy. Representative examples include polyarteritis nodosa, temporal arteritis, Wegener granulomatosis, Kawasaki disease, Takayasu arteritis, and Henoch-Schonlein purpura.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DC86-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-10","modifiedBy":"CZECHS","dateModified":"2008-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D47F93B-99F7-2D84-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Malignancy","valueDescription":"Malignant Neoplasm","ValueMeaning":{"publicId":"2749852","version":"1","preferredName":"Malignant Neoplasm","longName":"2749852","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D47F93B-9A03-2D84-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D47F93B-9A1C-2D84-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D47F93B-9A28-2D84-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"CZECHS","dateModified":"2008-05-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2749848","version":"1","preferredName":"Polymyositis Dermatomyositis Involvement Type","preferredDefinition":"Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY, NERVOUS SYSTEM); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9):A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6):To have a connection by participation or association or use; sharing in an activity or process.:Type; a subdivision of a particular kind of thing.","longName":"C26925:C26744:C25548:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymyositis","conceptCode":"C26925","definition":"An idiopathic inflammatory disorder affecting the muscles. It presents with symmetrical proximal muscle weakness and elevated skeletal muscle enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Dermatomyositis","conceptCode":"C26744","definition":"Inflammation of the skin and muscle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Involvement","conceptCode":"C25548","definition":"To have a connection by participation or association or use; sharing in an activity or process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D47F93B-9968-2D84-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"ONEDATA","dateModified":"2008-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D47F93B-9979-2D84-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:resultClassificationCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"For the polymyositis-dermatom","type":"Preferred Question Text","description":"For the polymyositis-dermatomyositis, what was the involved organ or clinical problem?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2749891","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.resultClassificationCode WHERE PerformedDiagnosis.value = \"polymyositis-dermatomyositis\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D4A0EF8-45AA-69AB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-15","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}